Literature DB >> 9233570

Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases.

J T Reilly1, J A Snowden, R L Spearing, P M Fitzgerald, N Jones, A Watmore, A Potter.   

Abstract

The prognostic significance of cytogenetic abnormalities was determined in 106 patients with well-characterized idiopathic myelofibrosis who were successfully karyotyped at diagnosis. 35% of the cases exhibited a clonal abnormality (37/106), whereas 65% (69/106) had a normal karyotype. Three characteristic defects, namely del(13q) (nine cases), del(20q) (eight cases) and partial trisomy 1q (seven cases), were present in 64.8% (24/37) of patients with clonal abnormalities. Kaplan-Meier plots and log rank analysis demonstrated an abnormal karyotype to be an adverse prognostic variable (P<0.001). Of the eight additional clinical and haematological parameters recorded at diagnosis, age (P<0.01), anaemia (haemoglobin < or = 10 g/dl: P<0.001), platelet (< or = 100 x 10(9)/l, P<0.0001) and leucocyte count (> 10.3 x 10(9)/l; P=0.06) were also associated with a shorter survival. In contrast, sex, spleen and liver size, and percentage blast cells were not found to be significant. Multivariate analysis, using Cox's regression, revealed karyotype, haemoglobin concentration, platelet and leucocyte counts to retain their unfavourable prognostic significance. A simple and useful schema for predicting survival in idiopathic myelofibrosis has been produced by combining age, haemoglobin concentration and karyotype with median survival times varying from 180 months (good-risk group) to 16 months (poor-risk group).

Entities:  

Mesh:

Year:  1997        PMID: 9233570     DOI: 10.1046/j.1365-2141.1997.1722990.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Prognostication in primary myelofibrosis.

Authors:  Francisco Cervantes; Arturo Pereira
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

Review 3.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors.

Authors:  Vikas Gupta; Parameswaran Hari; Ronald Hoffman
Journal:  Blood       Date:  2012-06-14       Impact factor: 22.113

4.  Primary chronic myelofibrosis: clinical and prognostic evaluation in 336 Japanese patients.

Authors:  T Okamura; N Kinukawa; Y Niho; H Mizoguchi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

5.  Usefulness of spleen volume measured by computed tomography for predicting clinical outcome in primary myelofibrosis.

Authors:  Moo-Kon Song; Joo-Seop Chung; Sung-Nam Lim; Gyeong-Won Lee; Sang-Min Lee; Nam-Kyung Lee; Jae-Cheol Choi; So-Yeon Oh
Journal:  Int J Hematol       Date:  2016-06-27       Impact factor: 2.490

6.  Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

Authors:  Hiroto Inaba; Yinmei Zhou; Oussama Abla; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Eveline de Bont; Tai-Tsung Chang; Ursula Creutzig; Michael Dworzak; Sarah Elitzur; Alcira Fynn; Erik Forestier; Henrik Hasle; Der-Cherng Liang; Vincent Lee; Franco Locatelli; Riccardo Masetti; Barbara De Moerloose; Dirk Reinhardt; Laura Rodriguez; Nadine Van Roy; Shuhong Shen; Takashi Taga; Daisuke Tomizawa; Allen E J Yeoh; Martin Zimmermann; Susana C Raimondi
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

7.  The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.

Authors:  Constantine S Tam; Lynne V Abruzzo; Katherine I Lin; Jorge Cortes; Alice Lynn; Michael J Keating; Deborah A Thomas; Sherry Pierce; Hagop Kantarjian; Srdan Verstovsek
Journal:  Blood       Date:  2009-01-08       Impact factor: 22.113

8.  Chromosome 5q deletion is extremely rare in patients with myelofibrosis.

Authors:  Koichi Takahashi; Jorge Cortes; Sherry Pierce; Lynne Abruzzo; Hagop Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2013-02-04       Impact factor: 3.156

9.  Unbalanced jumping translocation involving 3q in myeloproliferative disease.

Authors:  Peter McGrattan; Mervyn Humphreys; Donald Hull
Journal:  Med Oncol       Date:  2008-05-29       Impact factor: 3.064

Review 10.  Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia).

Authors:  Jan Jacques Michiels; Juergen Thiele
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.